MorNuCo's program of technology development is focused on innovative solutions to better health and well-being based on a family of cell-surface ECTO-NOX (ENOX) proteins with therapeutic and diagnostic potential for the principle disorders of aging, with emphasis on cancer, as well as cardiovascular and neurodegenerative diseases. MorNuCo's approach is to detect early before the disease progresses and to begin treatment well in advance of life-threatening symptoms.